Health & Medicine Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health & Medicine Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acne
Positive Actiza phase III trial results reported
October 27th, 2003
Connetics Corporation (CNCT) announced the positive outcome of a phase III clinical trial evaluating Actiza, an investigational new drug formulation of 1% clindamycin delivered in the company's proprietary Versafoam delivery system, as a potential new topical treatment for acne. The 12-week, double-blinded, active- and placebo-controlled trial included 1026 patients at 18 centers across the U.S. The trial was designed to demonstrate that Actiza was not inferior to Clindagel (clindamycin phosphate 1% topical gel) as measured by the primary endpoints of Investigator's Static Global Assessment (ISGA) and percent reduction in lesion counts (total, inflammatory and...
Source: Health & Medicine Week (2003-10-27)
|
